Last reviewed · How we verify

NCT05300841

The Effect of Pretreatment With Dydrogesterone Vs Combined Estradiol Valerate and Dydrogestrone on Clinical Pregnancy Outcome of ICSI in PCOS Patients"

Status unknown EARLY_PHASE1 Last updated 14 April 2022
What this trial tests

EARLY_PHASE1 trial testing dydrogesterone 20 mg /d (Duphaston, Abott Healthcare , Egypt) in PCOS in 500 participants. Status unknown.

Timeline
1 May 2022
Primary endpoint
1 April 2023
1 May 2023

Quick facts

Lead sponsorSohag University
PhaseEARLY_PHASE1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment500
Start date1 May 2022
Primary completion1 April 2023
Estimated completion1 May 2023

Drugs / interventions tested

Conditions studied

Sponsor

Sohag University

Who can join

Adults 18 to 35, female only, with PCOS or ICSI. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To analyze the effect of pretreatment with dydrogesterone vs combined estradiol valerate and dydrogesterone on embryologic parameters, chemical and clinical pregnancy rates of ICSI in women with PCOS.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for PCOS

Currently open trials in the same condition.

Other Sohag University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05300841.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing